Floatz logo

mt027

Pleural Mesothelioma

Suzhou Maximum Bio-tech Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Pleural Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
AstraZeneca
Phase 2BB
Carboplatin
AstraZeneca
Phase 2BB
Pembrolizumab
NuCana plc
Phase 2B
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 2B
Atezolizumab
Swiss Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

mt027 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
pleural neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →